Roopa Shivashankar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Roopa Shivashankar has a total of 237 co-authors. Here are the top co-authors by number of shared publications:
- Dorairaj Prabhakaran
Centre for Chronic Disease Control
16 shared publications - Mohammed Kumail Ali
Hubert Department of Global Health Emory University Rollins School of Public Health Atlanta Georgia USA
11 shared publications - Nikhil Tandon
Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi India
11 shared publications - Kabayam M. Venkat Narayan
Emory Global Diabetes Research Center, Woodruff Health Sciences Center and Emory University, Atlanta, USA
9 shared publications Nikhil Tandon
All India Institute of Medical Sciences
6 shared publications- Vamadevan S. Ajay
Centre for Chronic Disease Control, New Delhi, 110016, India
5 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Springer Nature in BMC Health Services Research
Implementing a multifaceted, comprehensive, appropriate care package for people with advanced and terminal illnesses needing intensive care support in India: protocol for a multiphase mixed-methods implementation study
Background: People with advanced or terminal illnesses may experience critical deterioration for which admission to intensive care, escalation of life-sustaining treatment, or continuation of invasive treatment offers limited clinically meaningful benefit or is inconsistent with their values and goals. Indian intensive care units (ICUs) vary substantially in governance, resources, sociocultural context, and access to specialist palliative care. Consequently, evidence-based end-of-life and palliative care practices are implemented inconsistently. This study was designed to co-develop, implement, and evaluate a context-sensitive care package for people with advanced or terminal illnesses who require ICU support. Methods: Implementing a Multifaceted, Comprehensive, Appropriate Care Package for People with Advanced and Terminal Illnesses Needing Intensive Care Support in India (MATHRU) was designed as a five-year, multicentre, multiphase, sequential mixed-methods implementation study. The intervention—the Multifaceted, Comprehensive, Appropriate Care Package (MCACP)—comprised seven domains: prognostication and recognition; interdisciplinary review and consensus; communication; shared decision-making; comprehensive anticipatory care planning; care delivery; and care evaluation and learning. Phase 1 used evidence synthesis, a two-step Delphi process, Nominal Group Technique, human-centred co-design, and usability testing to develop and specify the intervention. Phase 2 piloted MCACP in one open and one closed ICU. Phases 3 and 4 were designed to evaluate implementation across four ICUs with established palliative care access and four without, using mixed-methods process evaluation and a quasi-experimental pre–post effectiveness design, respectively. Phase 5 was designed to develop a national technical resource hub and a minimum viable set of interventions. The study was informed by Medical Research Council guidance for complex interventions, the Consolidated Framework for Implementation Research, Normalization Process Theory, and the Implementation Research Logic Model. Implementation outcomes included feasibility, acceptability, fidelity, reach, workflow compatibility and normalisation. Patient, family, and system outcomes included ICU Quality of Dying and Death, Family Satisfaction in the ICU, care process indicators, resource utilisation, and costs. The planned effectiveness sample was 150 patient episodes per ICU in each pre- and post-implementation period. At the time of revision, Phases 1 and 2 were ongoing, whereas Phases 3 and 4 had not commenced. Discussion: MATHRU was designed to evaluate whether a defined but adaptable appropriate-care package can be integrated across heterogeneous Indian ICUs. Its non-randomised design was recognised as susceptible to secular trends, regression to the mean, and residual confounding; the findings were therefore intended to be interpreted using covariate-adjusted analyses alongside data on context, fidelity, reach, and implementation mechanisms. Trial registration: Clinical Trials Registry–India: CTRI/2025/06/107155. Prospectively registered on 11 June 2025; protocol version 1.0.
- 12 October 2026
- Published by Springer Nature in BMC Health Services Research
Open AccessImplementing a multifaceted, comprehensive, appropriate care package for people with advanced and terminal illnesses needing intensive care support in India: protocol for a multiphase mixed-methods implementation study
Background: People with advanced or terminal illnesses may experience critical deterioration for which admission to intensive care, escalation of life-sustaining treatment, or continuation of invasive treatment offers limited clinically meaningful benefit or is inconsistent with their values and goals. Indian intensive care units (ICUs) vary substantially in governance, resources, sociocultural context, and access to specialist palliative care. Consequently, evidence-based end-of-life and palliative care practices are implemented inconsistently. This study was designed to co-develop, implement, and evaluate a context-sensitive care package for people with advanced or terminal illnesses who require ICU support. Methods: Implementing a Multifaceted, Comprehensive, Appropriate Care Package for People with Advanced and Terminal Illnesses Needing Intensive Care Support in India (MATHRU) was designed as a five-year, multicentre, multiphase, sequential mixed-methods implementation study. The intervention—the Multifaceted, Comprehensive, Appropriate Care Package (MCACP)—comprised seven domains: prognostication and recognition; interdisciplinary review and consensus; communication; shared decision-making; comprehensive anticipatory care planning; care delivery; and care evaluation and learning. Phase 1 used evidence synthesis, a two-step Delphi process, Nominal Group Technique, human-centred co-design, and usability testing to develop and specify the intervention. Phase 2 piloted MCACP in one open and one closed ICU. Phases 3 and 4 were designed to evaluate implementation across four ICUs with established palliative care access and four without, using mixed-methods process evaluation and a quasi-experimental pre–post effectiveness design, respectively. Phase 5 was designed to develop a national technical resource hub and a minimum viable set of interventions. The study was informed by Medical Research Council guidance for complex interventions, the Consolidated Framework for Implementation Research, Normalization Process Theory, and the Implementation Research Logic Model. Implementation outcomes included feasibility, acceptability, fidelity, reach, workflow compatibility and normalisation. Patient, family, and system outcomes included ICU Quality of Dying and Death, Family Satisfaction in the ICU, care process indicators, resource utilisation, and costs. The planned effectiveness sample was 150 patient episodes per ICU in each pre- and post-implementation period. At the time of revision, Phases 1 and 2 were ongoing, whereas Phases 3 and 4 had not commenced. Discussion: MATHRU was designed to evaluate whether a defined but adaptable appropriate-care package can be integrated across heterogeneous Indian ICUs. Its non-randomised design was recognised as susceptible to secular trends, regression to the mean, and residual confounding; the findings were therefore intended to be interpreted using covariate-adjusted analyses alongside data on context, fidelity, reach, and implementation mechanisms. Trial registration: Clinical Trials Registry–India: CTRI/2025/06/107155. Prospectively registered on 11 June 2025; protocol version 1.0.
- Open Access
- 12 March 2026
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 21 (1) , 19
Financial Burden, Out-of-Pocket Health Spending, and Household Economic Well-Being in Heart Failure Patients in India: A Multicentre Cross-Sectional Survey
Background: Heart failure (HF) is a complex clinical condition requiring resource-intensive management and substantial health expenditure. The adverse economic impact of medical care on patients or financial burden is increasingly recognised as a significant non-clinical entity affecting HF management in low- and middle-income countries (LMIC). We explored the factors associated with Financial Burden (FB) in HF patients in India. Methods: We recruited HF patients from 21 hospitals across India, selected to reflect regional diversity and varying stages of epidemiological transition. Trained personnel collected clinical and economic data using a validated and structured questionnaire. Expenditures were recorded in Indian rupees (INR) and converted to international dollars (INT$). Results: We recruited 1,859 participants. Nearly one-third of participants (30.2%) were women. The mean age was 55.9 (11.3) years, and the mean duration of formal education was 11.3 (3.8) years. Health insurance coverage was reported in one-third (32.2%) of the study population. The average annual out-of-pocket (OOP) expenditure was INR 1,06,566 (INT$ 4,709.10), constituting 92.6% (95% CI: 92.5–92.7) of the total health expenditure. Compared to the previous year, a decline in monthly income was reported by 32.3% of individuals and 36.2% of households. Catastrophic health spending (CHS) and distress financing (DF) were observed in 37.7% (35.5–39.9) and 17.7% (15.9–19.4) of the households, respectively. However, CHS and DF were lower [30.8% (26.2–35.4) and 13.6% (10.2–17.0), respectively] among those with health insurance compared to the uninsured [40.3% (37.6–43.0) and 18.9% (16.7–21.1), respectively]. Conclusion: Seven out of 10 HF patients in India lack financial health protection. OOP expenditures, accounting for over 90% of total health spending, contribute significantly to economic distress in HF patients. Financial burden, affecting more than one-third of HF patients, carries profound implications for individual well-being. Addressing this financial burden, including CHS and DF, is essential for improving clinical outcomes and ensuring health equity.
- 12 March 2026
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 21 (1) , 19
Open AccessFinancial Burden, Out-of-Pocket Health Spending, and Household Economic Well-Being in Heart Failure Patients in India: A Multicentre Cross-Sectional Survey
Background: Heart failure (HF) is a complex clinical condition requiring resource-intensive management and substantial health expenditure. The adverse economic impact of medical care on patients or financial burden is increasingly recognised as a significant non-clinical entity affecting HF management in low- and middle-income countries (LMIC). We explored the factors associated with Financial Burden (FB) in HF patients in India. Methods: We recruited HF patients from 21 hospitals across India, selected to reflect regional diversity and varying stages of epidemiological transition. Trained personnel collected clinical and economic data using a validated and structured questionnaire. Expenditures were recorded in Indian rupees (INR) and converted to international dollars (INT$). Results: We recruited 1,859 participants. Nearly one-third of participants (30.2%) were women. The mean age was 55.9 (11.3) years, and the mean duration of formal education was 11.3 (3.8) years. Health insurance coverage was reported in one-third (32.2%) of the study population. The average annual out-of-pocket (OOP) expenditure was INR 1,06,566 (INT$ 4,709.10), constituting 92.6% (95% CI: 92.5–92.7) of the total health expenditure. Compared to the previous year, a decline in monthly income was reported by 32.3% of individuals and 36.2% of households. Catastrophic health spending (CHS) and distress financing (DF) were observed in 37.7% (35.5–39.9) and 17.7% (15.9–19.4) of the households, respectively. However, CHS and DF were lower [30.8% (26.2–35.4) and 13.6% (10.2–17.0), respectively] among those with health insurance compared to the uninsured [40.3% (37.6–43.0) and 18.9% (16.7–21.1), respectively]. Conclusion: Seven out of 10 HF patients in India lack financial health protection. OOP expenditures, accounting for over 90% of total health spending, contribute significantly to economic distress in HF patients. Financial burden, affecting more than one-third of HF patients, carries profound implications for individual well-being. Addressing this financial burden, including CHS and DF, is essential for improving clinical outcomes and ensuring health equity.
- Open Access
- 27 October 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-10
Changing patterns in health-seeking behaviour and prescription practices for treatment of hypertension in nine districts – insights from India Hypertension Control Initiative, 2018-19 and 2023-24
The India Hypertension Control Initiative (IHCI) aimed to strengthen public sector primary care for hypertension treatment and control. Our study describes changes in health-seeking behaviour, prescription practices, and key predictors influencing treatment adoption in the public sector using data from IHCI repeat cross-sectional surveys. We conducted baseline (2018-19) and follow-up (2023-24) surveys in nine districts across five Phase I states in India - two districts each from Punjab, Madhya Pradesh, Telangana, and Kerala, and one from Maharashtra. We conducted the survey among 3,900 adults (18–69 years) per district at two time points. We computed frequencies and proportions for socio-demographic variables, healthcare utilisation, blood pressure (BP) control, drug availability, medication costs, and prescription practices. We used a log-binomial model to estimate unadjusted and adjusted prevalence ratios (PRs, APRs) with 95% confidence intervals for factors influencing care-seeking for hypertension in government facilities. Among 2,873 baseline and 3,276 follow-up respondents, the proportion seeking treatment at government facilities increased from 20% to 32%. Individuals on treatment were 1.5 times more likely to use government facilities in 2023-24 than in 2018-19 (aPR 1.54, 95% CI: 1.4–1.7). BP control improved in government (37% to 48%) and non-government (35% to 47%) facilities. Drug availability (always available) in government facilities rose from 72% (425/588) to 81% (844/1041), with Amlodipine 5 mg remaining the most prescribed drug (18%). The proportion of individuals paying for medications dropped from 47% to 9%. There was increased public sector use, improved BP control, enhanced drug availability, and reduced costs, possibly due to IHCI interventions. We recommend using representative surveys for NCD surveillance to monitor healthcare utilisation patterns and assess the impact of interventions on hypertension outcomes. Keywords Blood Pressure; Hypertension; Public Sector; Primary Health Care; Drug Prescriptions; Patient Acceptance of Health Care; India
- 27 October 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-10
Open AccessChanging patterns in health-seeking behaviour and prescription practices for treatment of hypertension in nine districts – insights from India Hypertension Control Initiative, 2018-19 and 2023-24
The India Hypertension Control Initiative (IHCI) aimed to strengthen public sector primary care for hypertension treatment and control. Our study describes changes in health-seeking behaviour, prescription practices, and key predictors influencing treatment adoption in the public sector using data from IHCI repeat cross-sectional surveys. We conducted baseline (2018-19) and follow-up (2023-24) surveys in nine districts across five Phase I states in India - two districts each from Punjab, Madhya Pradesh, Telangana, and Kerala, and one from Maharashtra. We conducted the survey among 3,900 adults (18–69 years) per district at two time points. We computed frequencies and proportions for socio-demographic variables, healthcare utilisation, blood pressure (BP) control, drug availability, medication costs, and prescription practices. We used a log-binomial model to estimate unadjusted and adjusted prevalence ratios (PRs, APRs) with 95% confidence intervals for factors influencing care-seeking for hypertension in government facilities. Among 2,873 baseline and 3,276 follow-up respondents, the proportion seeking treatment at government facilities increased from 20% to 32%. Individuals on treatment were 1.5 times more likely to use government facilities in 2023-24 than in 2018-19 (aPR 1.54, 95% CI: 1.4–1.7). BP control improved in government (37% to 48%) and non-government (35% to 47%) facilities. Drug availability (always available) in government facilities rose from 72% (425/588) to 81% (844/1041), with Amlodipine 5 mg remaining the most prescribed drug (18%). The proportion of individuals paying for medications dropped from 47% to 9%. There was increased public sector use, improved BP control, enhanced drug availability, and reduced costs, possibly due to IHCI interventions. We recommend using representative surveys for NCD surveillance to monitor healthcare utilisation patterns and assess the impact of interventions on hypertension outcomes. Keywords Blood Pressure; Hypertension; Public Sector; Primary Health Care; Drug Prescriptions; Patient Acceptance of Health Care; India
- 5 February 2024
- Published by Springer Nature in Acta Diabetologica
- Vol. 61 (5) , 577-586
Association of pro-inflammatory cytokines, adipokines and hepatokine with incident diabetes in India: a nested case–control study within CARRS cohort
Aims To study the association of pro-inflammatory markers with incident diabetes in India. Methods We did a nested case–control study within the CARRS (Centre for Ardiometabolic Risk Reduction in South Asia) cohort. Of the 5739 diabetes-free individuals at the baseline, 216 participants with incident diabetes and 432 age-, gender- and city-matched controls at 2-year follow-up were included. We measured high sensitive C-reactive protein (hsCRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 ( MCP-1), adiponectin, leptin and fetuin-A in the stored baseline blood samples. We did multivariate conditional logistic regression to estimate association of inflammatory markers (as quartiles) and incident diabetes. Covariates were baseline fasting plasma glucose (FPG) and lipids, body mass index (BMI), family history of diabetes, smoking and alcohol use. Results Baseline hsCRP and TNF-α were higher, and IL-6 and adiponectin were lower among cases vs. controls. In multivariate conditional logistic regression models, only quartile-3 (odds ratio [OR]: 2.96 [95% CI:1.39, 6.30]) and quartile-4 (OR: 2.58 [95% CI: 1.15, 5.79]) of TNF-α and quartile-4 of MCP-1 (OR: 2.55 [95% CI: 1.06, 6.16]) were positively associated with diabetes after adjusting for baseline FPG and BMI. These associations did not remain after adjusting for family history. High level (quartile-4) of IL-6 was negatively associated with diabetes after adjusting for all factors (OR: 0.18 [95% CI: 0.06, 0.55]). Conclusions Higher TNF-α and MCP-1 levels and lower IL-6 were associated with higher risk of developing diabetes. Better understanding and potential methods of addressing these biomarkers, especially in relation to family history, are needed to address diabetes in South Asians.
- 5 February 2024
- Published by Springer Nature in Acta Diabetologica
- Vol. 61 (5) , 577-586
Association of pro-inflammatory cytokines, adipokines and hepatokine with incident diabetes in India: a nested case–control study within CARRS cohort
Aims To study the association of pro-inflammatory markers with incident diabetes in India. Methods We did a nested case–control study within the CARRS (Centre for Ardiometabolic Risk Reduction in South Asia) cohort. Of the 5739 diabetes-free individuals at the baseline, 216 participants with incident diabetes and 432 age-, gender- and city-matched controls at 2-year follow-up were included. We measured high sensitive C-reactive protein (hsCRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 ( MCP-1), adiponectin, leptin and fetuin-A in the stored baseline blood samples. We did multivariate conditional logistic regression to estimate association of inflammatory markers (as quartiles) and incident diabetes. Covariates were baseline fasting plasma glucose (FPG) and lipids, body mass index (BMI), family history of diabetes, smoking and alcohol use. Results Baseline hsCRP and TNF-α were higher, and IL-6 and adiponectin were lower among cases vs. controls. In multivariate conditional logistic regression models, only quartile-3 (odds ratio [OR]: 2.96 [95% CI:1.39, 6.30]) and quartile-4 (OR: 2.58 [95% CI: 1.15, 5.79]) of TNF-α and quartile-4 of MCP-1 (OR: 2.55 [95% CI: 1.06, 6.16]) were positively associated with diabetes after adjusting for baseline FPG and BMI. These associations did not remain after adjusting for family history. High level (quartile-4) of IL-6 was negatively associated with diabetes after adjusting for all factors (OR: 0.18 [95% CI: 0.06, 0.55]). Conclusions Higher TNF-α and MCP-1 levels and lower IL-6 were associated with higher risk of developing diabetes. Better understanding and potential methods of addressing these biomarkers, especially in relation to family history, are needed to address diabetes in South Asians.
- Open Access
- 8 January 2024
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 19 (1) , 30
India Hypertension Control Initiative: Blood Pressure Control Using Drug and Dose-Specific Standard Treatment Protocol at Scale in Punjab and Maharashtra, India, 2022
Background: Hypertension treatment coverage is low in India. A stepwise simple treatment protocol is one of the strategies to improve hypertension treatment in primary care. We estimated the effectiveness of various protocol steps to achieve blood pressure (BP) control in public sector health facilities in Punjab and Maharashtra, India, where the India Hypertension Control Initiative (IHCI) was implemented. Methods: We analyzed the records of people enrolled for hypertension treatment and follow-up under IHCI between January 2018 and December 2021 in public sector primary and secondary care facilities across 23 districts from two states. Each state followed a different treatment protocol. We calculated the proportion with controlled BP at each step of the protocol. We also estimated the mean decline in BP pre- and post-treatment. Results: Of 281,209 patients initiated on amlodipine 5 mg, 159,292 continued on protocol drugs and came for a follow-up visit during the first quarter of 2022. Of 33,450 individuals who came for the follow-up in Punjab and 125,842 in Maharashtra, 70% and 76% had controlled BP, respectively, at the first step with amlodipine 5 mg. In Punjab, at the second step with amlodipine 10 mg, the cumulative BP control increased to 75%. A similar 5% (76%–81%) increase was seen in the second step after adding telmisartan 40 mg in Maharashtra. Overall, the mean (SD) systolic blood pressure (SBP) decreased by 16 mmHg from 148 (15) mmHg at the baseline in Punjab. In Maharashtra, the decline in the mean (SD) SBP was about 15 mmHg from the 144 (18) mmHg baseline. Conclusion: Simple drug- and dose-specific protocols helped achieve a high control rate among patients retained in care under program conditions. We recommend treatment protocols starting with a single low-cost drug and escalating with the same or another antihypertensive drug depending on the cost and availability.
- 8 January 2024
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 19 (1) , 30
Open AccessIndia Hypertension Control Initiative: Blood Pressure Control Using Drug and Dose-Specific Standard Treatment Protocol at Scale in Punjab and Maharashtra, India, 2022
Background: Hypertension treatment coverage is low in India. A stepwise simple treatment protocol is one of the strategies to improve hypertension treatment in primary care. We estimated the effectiveness of various protocol steps to achieve blood pressure (BP) control in public sector health facilities in Punjab and Maharashtra, India, where the India Hypertension Control Initiative (IHCI) was implemented. Methods: We analyzed the records of people enrolled for hypertension treatment and follow-up under IHCI between January 2018 and December 2021 in public sector primary and secondary care facilities across 23 districts from two states. Each state followed a different treatment protocol. We calculated the proportion with controlled BP at each step of the protocol. We also estimated the mean decline in BP pre- and post-treatment. Results: Of 281,209 patients initiated on amlodipine 5 mg, 159,292 continued on protocol drugs and came for a follow-up visit during the first quarter of 2022. Of 33,450 individuals who came for the follow-up in Punjab and 125,842 in Maharashtra, 70% and 76% had controlled BP, respectively, at the first step with amlodipine 5 mg. In Punjab, at the second step with amlodipine 10 mg, the cumulative BP control increased to 75%. A similar 5% (76%–81%) increase was seen in the second step after adding telmisartan 40 mg in Maharashtra. Overall, the mean (SD) systolic blood pressure (SBP) decreased by 16 mmHg from 148 (15) mmHg at the baseline in Punjab. In Maharashtra, the decline in the mean (SD) SBP was about 15 mmHg from the 144 (18) mmHg baseline. Conclusion: Simple drug- and dose-specific protocols helped achieve a high control rate among patients retained in care under program conditions. We recommend treatment protocols starting with a single low-cost drug and escalating with the same or another antihypertensive drug depending on the cost and availability.
- Open Access
- 16 September 2023
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 158 (3) , 233-243
India’s tryst with salt: Dandi march to low sodium salts
Salt plays a critical role in India’s past as well as its present, from Dandi March to its role as a vehicle for micronutrient fortification. However, excess salt intake is a risk factor for high blood pressure and cardiovascular diseases (CVDs). Indians consume double the World Health Organization recommended daily salt (<5 g). India has committed to a 30 per cent reduction in sodium intake by 2025. Evidence based strategies for population sodium intake reduction require a moderate reduction in salt in – home cooked foods, packaged foods and outside-home foods. Reducing the sodium content in packaged food includes policy driven interventions such as front-of-package warning labels, food reformulation, marketing restrictions and taxation on high sodium foods. For foods outside of the home, setting standards for foods purchased and served by schemes like mid-day meals can have a moderate impact. For home cooked foods (the major source of sodium), strategies include advocacy for reducing salt intake. In addition to mass media campaigns for awareness generation, substituting regular salt with low sodium salt (LSS) has the potential to reduce salt intake even in the absence of a major shift in consumer behaviour. LSS substitution effectively lowers blood pressure and thus reduces the risk of CVDs. Further research is required on the effect of LSS substitutes on patients with chronic kidney disease. India needs an integrated approach to sodium reduction that uses evidence based strategies and can be implemented sustainably at scale. This will be possible only through scientific research, governmental leadership and a responsive evidence-to-action approach through a multi-stakeholder coalition.
- 16 September 2023
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 158 (3) , 233-243
Open AccessIndia’s tryst with salt: Dandi march to low sodium salts
Salt plays a critical role in India’s past as well as its present, from Dandi March to its role as a vehicle for micronutrient fortification. However, excess salt intake is a risk factor for high blood pressure and cardiovascular diseases (CVDs). Indians consume double the World Health Organization recommended daily salt (<5 g). India has committed to a 30 per cent reduction in sodium intake by 2025. Evidence based strategies for population sodium intake reduction require a moderate reduction in salt in – home cooked foods, packaged foods and outside-home foods. Reducing the sodium content in packaged food includes policy driven interventions such as front-of-package warning labels, food reformulation, marketing restrictions and taxation on high sodium foods. For foods outside of the home, setting standards for foods purchased and served by schemes like mid-day meals can have a moderate impact. For home cooked foods (the major source of sodium), strategies include advocacy for reducing salt intake. In addition to mass media campaigns for awareness generation, substituting regular salt with low sodium salt (LSS) has the potential to reduce salt intake even in the absence of a major shift in consumer behaviour. LSS substitution effectively lowers blood pressure and thus reduces the risk of CVDs. Further research is required on the effect of LSS substitutes on patients with chronic kidney disease. India needs an integrated approach to sodium reduction that uses evidence based strategies and can be implemented sustainably at scale. This will be possible only through scientific research, governmental leadership and a responsive evidence-to-action approach through a multi-stakeholder coalition.
- 3 June 2023
- Published by Springer Nature
- p. 273-283
Diabetes Management in Asia
- Open Access
- 28 April 2023
- Published by Scientific Scholar in The National Medical Journal of India
- Vol. 35 (6) , 357-363
Essential medicines for cardiovascular diseases in India: Rapid appraisal of policies and processes at the subnational level
Background: The burden of cardiovascular diseases (CVDs) and response to health systems vary widely at the subnational level in India. Our study aimed to assess the variation in state-level access to medicines for CVDs by comparing the essential medicines lists (EMLs) at the national and subnational levels in India and by rapid appraisal of the existing policies and processes of drug procurement. Methods: We assessed the inclusion of six classes of medicines for CVDs in the recent and publicly available national and subnational EMLs from July to September 2018 in the states of Telangana and Madhya Pradesh. We examined the drug procurement and distribution policies and processes using documentary review and five key informant interviews between March and June 2018. Results: The WHO’s EML, India’s national EML, and 21 of 28 publicly available (75%) Indian state and Union Territory EMLs included all six classes of essential medicines for CVDs. However, some medicines were not included in the policy packages of essential medicines meant for primary health centres. Both the states used centralized tendering and decentralized distribution as part of the public sector drug procurement process. The requirement was based on the previous year’s consumption. The approximate time between procurement planning and distribution was 7–8 months in both the states. Conclusion: Substantial variation exists in the selection of drugs for CVDs in EMLs at the subnational level in India. Improving forecasting techniques for requirement of medicines and reducing time lags between forecasting and distribution to health facilities may allow for better access to essential medicines.
- 28 April 2023
- Published by Scientific Scholar in The National Medical Journal of India
- Vol. 35 (6) , 357-363
Open AccessEssential medicines for cardiovascular diseases in India: Rapid appraisal of policies and processes at the subnational level
Background: The burden of cardiovascular diseases (CVDs) and response to health systems vary widely at the subnational level in India. Our study aimed to assess the variation in state-level access to medicines for CVDs by comparing the essential medicines lists (EMLs) at the national and subnational levels in India and by rapid appraisal of the existing policies and processes of drug procurement. Methods: We assessed the inclusion of six classes of medicines for CVDs in the recent and publicly available national and subnational EMLs from July to September 2018 in the states of Telangana and Madhya Pradesh. We examined the drug procurement and distribution policies and processes using documentary review and five key informant interviews between March and June 2018. Results: The WHO’s EML, India’s national EML, and 21 of 28 publicly available (75%) Indian state and Union Territory EMLs included all six classes of essential medicines for CVDs. However, some medicines were not included in the policy packages of essential medicines meant for primary health centres. Both the states used centralized tendering and decentralized distribution as part of the public sector drug procurement process. The requirement was based on the previous year’s consumption. The approximate time between procurement planning and distribution was 7–8 months in both the states. Conclusion: Substantial variation exists in the selection of drugs for CVDs in EMLs at the subnational level in India. Improving forecasting techniques for requirement of medicines and reducing time lags between forecasting and distribution to health facilities may allow for better access to essential medicines.
- Open Access
- 2 August 2022
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 17 (1) , 52
Cardiovascular Health in India – a Report Card from Three Urban and Rural Surveys of 22,144 Adults
Background: Markers of ideal cardiovascular health (CVH) predict cardiovascular events. We estimated the prevalence of ideal CVH markers in two levels of cities and villages in India.Methods: We did pooled analysis of individual-level data from three cross sectional surveys of adults ≥ 30 years over 2010–14 (CARRS: Centre for cArdiometabolic Risk Reduction in South Asia; UDAY and Solan Surveillance Study) representing metropolitan cities; smaller cities and rural areas in diverse locations of India. We defined ideal CVH using modified American Heart Association recommendations: not smoking, ≥ 5 servings of fruits and vegetables (F&V), high physical activity (PA), body mass index (BMI) <25 Kg/m2, blood pressure (BP) <120/80 mm Hg, fasting plasma glucose (FPG) <100 mg/dl, and total cholesterol (TC) <200 mg/dL. We estimated (1) age-and sex-standardized prevalence of ideal CVH and (2) prevalence of good (≥6 markers), moderate (4–5), and poor CVH (≤3) adjusted for age, sex, education, and stratified by setting and asset tertiles.Results: Of the total 22,144 participants, the prevalence of ideal CVH markers were: not smoking (76.7% [95% CI 76.1, 77.2]), consumed ≥5 F&V (4.2% [3.9, 4.5]), high PA (67.5% [66.8, 68.2]), optimum BMI (59.6% [58.9, 60.3]), ideal BP (34.5% [33.9, 35.2]), FPG (65.8% [65.1, 66.5]) and TC (65.4% [64.7, 66.1]). The mean number of ideal CVH metrics was 3.7(95% CI: 3.7, 3.8). Adjusted prevalence of good, moderate, and poor CVH, varied across settings: metropolitan (3.9%, 41.0%, and 55.1%), smaller cities (7.8%, 49.2%, and 43%), and rural (10.4%, 60.9%, and 28.7%) and across asset tertiles: Low (11.0%, 55.9%, 33.1%), Middle (6.3%, 52.2%, 41.5%), and High (5.0%, 46.4%, 48.7%), respectively.Conclusion: Achievement of ideal CVH varied, with higher prevalence in rural and lower asset tertiles. Multi-sectoral and targeted policy and program actions are needed to improve CVH in diverse contexts in India. Publisher’s Note: A correction article relating to this paper has been published and can be found at https://globalheartjournal.com/articles/10.5334/gh.1158/.
- 2 August 2022
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 17 (1) , 52
Open AccessCardiovascular Health in India – a Report Card from Three Urban and Rural Surveys of 22,144 Adults
Background: Markers of ideal cardiovascular health (CVH) predict cardiovascular events. We estimated the prevalence of ideal CVH markers in two levels of cities and villages in India.Methods: We did pooled analysis of individual-level data from three cross sectional surveys of adults ≥ 30 years over 2010–14 (CARRS: Centre for cArdiometabolic Risk Reduction in South Asia; UDAY and Solan Surveillance Study) representing metropolitan cities; smaller cities and rural areas in diverse locations of India. We defined ideal CVH using modified American Heart Association recommendations: not smoking, ≥ 5 servings of fruits and vegetables (F&V), high physical activity (PA), body mass index (BMI) <25 Kg/m2, blood pressure (BP) <120/80 mm Hg, fasting plasma glucose (FPG) <100 mg/dl, and total cholesterol (TC) <200 mg/dL. We estimated (1) age-and sex-standardized prevalence of ideal CVH and (2) prevalence of good (≥6 markers), moderate (4–5), and poor CVH (≤3) adjusted for age, sex, education, and stratified by setting and asset tertiles.Results: Of the total 22,144 participants, the prevalence of ideal CVH markers were: not smoking (76.7% [95% CI 76.1, 77.2]), consumed ≥5 F&V (4.2% [3.9, 4.5]), high PA (67.5% [66.8, 68.2]), optimum BMI (59.6% [58.9, 60.3]), ideal BP (34.5% [33.9, 35.2]), FPG (65.8% [65.1, 66.5]) and TC (65.4% [64.7, 66.1]). The mean number of ideal CVH metrics was 3.7(95% CI: 3.7, 3.8). Adjusted prevalence of good, moderate, and poor CVH, varied across settings: metropolitan (3.9%, 41.0%, and 55.1%), smaller cities (7.8%, 49.2%, and 43%), and rural (10.4%, 60.9%, and 28.7%) and across asset tertiles: Low (11.0%, 55.9%, 33.1%), Middle (6.3%, 52.2%, 41.5%), and High (5.0%, 46.4%, 48.7%), respectively.Conclusion: Achievement of ideal CVH varied, with higher prevalence in rural and lower asset tertiles. Multi-sectoral and targeted policy and program actions are needed to improve CVH in diverse contexts in India. Publisher’s Note: A correction article relating to this paper has been published and can be found at https://globalheartjournal.com/articles/10.5334/gh.1158/.
- Open Access
- 18 May 2022
- Published by Elsevier in Indian Heart Journal
- Vol. 74 (4) , 307-313
Association of family history of cardiometabolic diseases (CMDs) and individual health behaviours: Analysis of CARRS study from South Asia
- 18 May 2022
- Published by Elsevier in Indian Heart Journal
- Vol. 74 (4) , 307-313
Open AccessAssociation of family history of cardiometabolic diseases (CMDs) and individual health behaviours: Analysis of CARRS study from South Asia